我們已在上線！進一步了解

BioVie

BIVI

市值 US$1042萬

1.20 USD

+0.07

6.19%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

1.21

+0.01

0.83%

1天

6.19%

5天

-14.89%

1個月

-30.23%

3個月

-30.23%

6個月

-17.81%

今年迄今

-9.77%

1年

-35.14%

5年

-99.79%

10年

-99.88%

關於： BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.

員工： 13

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 13.3%

中性 80%

負面 6.7%

Proactive Investors

BioVie to present Long COVID and Parkinson's trial results at American Neurological Association meeting

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) will present results from two Phase 2 trials of its experimental drug bezisterim, in Long COVID and Parkinson's disease, at the American Neurological Association's annual meeting in San Diego. The company said both abstracts were accepted as poster presentations at ANA2026, which runs from October 17 to 20.

BioVie to present Long COVID and Parkinson's trial results at American Neurological Association meeting

BioVie to Present New Bezisterim Findings in Parkinson's Disease and Long COVID at the 2026 American Neurological Association Annual Meeting

CARSON CITY, Nev., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that two abstracts detailing results from the Company's ADDRESS-LC Phase 2 trial in Long COVID, and SUNRISE-PD Phase 2 trial of bezisterim in Parkinson's Disease have been accepted for presentation at ANA2026, the annual meeting of the American Neurological Association.

BioVie to Present New Bezisterim Findings in Parkinson's Disease and Long COVID at the 2026 American Neurological Association Annual Meeting

BioVie Inc. (BIVI) Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets Transcript

BioVie Inc. (BIVI) Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets Transcript

BioVie Inc. (BIVI) Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets Transcript

BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid Transcript

BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid Transcript

BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid Transcript

What's Going On With BioVie Stock on Tuesday?

Clinical-stage biopharmaceutical firm BioVie Inc. (NASDAQ:BIVI) stock is trading lower after the company shared topline results from its Phase 2 ADDRESS-LC study evaluating bezisterim in Long COVID patients.

What's Going On With BioVie Stock on Tuesday?

BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

Statistically significant benefits observed in bezisterim-treated Long COVID patients in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post‑exertional malaise

BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid

Conference call scheduled for Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time (ET) Conference call scheduled for Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time (ET)

BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid

Proactive Investors

BioVie advances Parkinson's Phase 3 development program with FDA engagement

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) told investors that it is preparing to advance its Phase 3 development program for bezisterim in Parkinson's disease and has requested an End-of-Phase 2 meeting with the US Food and Drug Administration. The company is working with Parkinson's disease clinical development experts to finalize the design of a Phase 3 trial.

BioVie advances Parkinson's Phase 3 development program with FDA engagement

BioVie Announces Update to Parkinson's Phase 3 Development Program

Company Corresponded with the FDA on an End of Phase 2 Meeting to Align on Phase 3 trial Design for Evaluation of Bezisterim in Early-stage Parkinson's Disease Company Corresponded with the FDA on an End of Phase 2 Meeting to Align on Phase 3 trial Design for Evaluation of Bezisterim in Early-stage Parkinson's Disease

BioVie Announces Update to Parkinson's Phase 3 Development Program

Proactive Investors

BioVie completes final patient visit in Phase 2 Long COVID trial

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that has completed the last on-treatment visit in its Phase 2 ADDRESS-LC clinical trial evaluating bezisterim in adults with Long COVID, with topline results targeted for release before the end of September 2026. The Carson City, Nevada-based clinical-stage company is developing therapies for neurological and neurodegenerative diseases.

BioVie completes final patient visit in Phase 2 Long COVID trial

查看新聞排名

價格圖表採用Lightweight Charts™實作